

From: stanmore.rec@hra.nhs.uk
To: [Dalbir Kaur \(Birmingham Clinical Trials Unit\)](#)
Subject: FW: IRAS Project ID 261576. HRA and HCRW Approval for the Amendment
Date: 23 June 2020 15:27:03

From: stanmore.rec@hra.nhs.uk <stanmore.rec@hra.nhs.uk>
Sent: 16 June 2020 16:04
To: a.m.turner@bham.ac.uk; researchgovernance@contacts.bham.ac.uk
Subject: IRAS Project ID 261576. HRA and HCRW Approval for the Amendment

Dear Dr Turner,

IRAS Project ID:	261576
Short Study Title:	Predict&Prevent AECOPD
Amendment No./Sponsor Ref:	1
Amendment Date:	12 May 2020
Amendment Type:	Substantial Non-CTIMP

I am pleased to confirm **HRA and HCRW Approval** for the above referenced amendment.

You should implement this amendment at NHS organisations in England and Wales, in line with the guidance in the amendment tool.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>.

Please contact amendments@hra.nhs.uk for any queries relating to the assessment of this amendment.

Kind regards

Dr Ashley Totenhofer
Workflow Monitoring Manager
Health Research Authority

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

E. amendments@hra.nhs.uk

W. www.hra.nhs.uk

Sign up to receive our newsletter [HRA Latest](#).

This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation..
